Novel thiazolidinone derivatives with an uncommon mechanism of inhibition towards HIV-1 reverse transcriptase

Letters in Drug Design and Discovery

Volumn 7, Issue 4, 2010, Pages 228-234

  Pitta, Eleni ^a   Crespan, Emmanuele ^b   Geronikaki, Athina ^a   Giovanni, Maga ^b   Samuele, Alberta ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b CNR   (Italy)

Author keywords

AIDS; Antiretroviral therapy; Enzyme kinetics; HAART; HIV 1 RT; NNRTIs

Indexed keywords

3 [4 (1 ADAMANTYL) 1,3 THIAZOL 2 YL] 2 (2,6 DICHLOR0PHENYL) 1,3 THIAZOLIDIN 4 ONE; 3 [4 (1 ADAMANTYL) 1,3 THIAZOL 2 YL] 2 (4 BROMOPHENYL) 1,3 THIAZOLIDIN 4 ONE; ANTIRETROVIRUS AGENT; NUCLEIC ACID; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ASSAY; ENZYME KINETICS; ENZYME SUBSTRATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NONHUMAN; ORGANIC CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTON NUCLEAR MAGNETIC RESONANCE; STEADY STATE; SYNTHESIS; THIN LAYER CHROMATOGRAPHY; WESTERN BLOTTING;

EID: 77949687060     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018010790945869     Document Type: Article

References (10)

1. Wainberg, M.A.: Sawyer, J.P.; Montaner, J.S.; Murphy, R.L.; Kuritzkes, D.R.; Raffi, F. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Antivir. Ther., 2005, 10, 13-28.
2. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers., 2004, 1, 44-64.
3. Martins, S.; Ramos, M.J.; Fernandes, P.A. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr. Med. Chem., 2008, 15, 1083-1095.
4. Bartlett, J.A.; Fath, M.J.; Demasi, R.; Hermes, A.; Quinn, J.; Mondou, E.; Rousseau, F. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS, 2006, 20, 2051-2064.
5. Maga, G.; Spadari, S. Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations. Curr. Drug Metab., 2002, 3, 73-95.
6. Zhan, P.; Liu, X.; Li, Z.; Pannecouque, C.; De Clercq E. Design strategies of novel NNRTIs to overcome drug resistance. Curr. Med. Chem., 2009, 16, 3903-3917.
7. Barreca, M.L.; Balzarini, J.; Chimirri, A.; De Clercq, E.; De Luca, L.; Holtje, H.D.; Holtje, M.; Monforte, A.M.; Monforte, P.; Pannecouque, C.; Rao, A.; Zappala, M. Design, synthesis, structureactivity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J. Med. Chem., 2002, 45, 5410-5413.
8. Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E. Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorg. Med. Chem., 2007, 15, 1725-1731.
9. Rawal, R.K.; Tripathi, R.; Katti, S.B.; Pannecouque, C.; De Clercq, E. Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin- 4-one analogues as anti-HIV-1 agents. Bioorg. Med. Chem., 2007, 15, 3134-3142.
10. Rawal, R.K.; Tripathi, R.K.; Katti, S.B.; Pannecouque, C.; De Clercq, E. Synthesis and biological evaluation of 2,3-diaryl substituted-1,3-thiazolidin-4- ones as anti-HIV agents. Med. Chem., 2007, 3, 355-363.